Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance.

ABSTRACT: The insulin-like growth factor pathway, regulated by a complex interplay of growth factors, cognate receptors, and binding proteins, is critically important for many of the hallmarks of cancer such as oncogenesis, cell division, growth, and antineoplastic resistance. Naturally, a number of clinical trials have sought to directly abrogate insulin-like growth factor receptor 1 (IGF-1R) function and/or indirectly mitigate its downstream mediators such as mTOR, PI3K, MAPK, and others under the assumption that such therapeutic interventions would provide clinical benefit, demonstrable by impaired tumor growth as well as prolonged progression-free and overall survival for patients. Though a small subset of patients enrolled within phase I or II clinical trials revealed dramatic clinical response

SUBMITTER: Ludwig JA 

PROVIDER: S-EPMC3759185 | biostudies-literature | 2011 Jul

REPOSITORIES: biostudies-literature